Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$117.14
-4.21-3.47%
Last update: Oct 1, 6:45 PM
$116.50
-4.85-4%
Incyte Corp (INCY) Stock Price, Quote, News & History
INCYNASDAQ
| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Incyte (NASDAQ:INCY) through any online brokerage.
Other companies in Incyte’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Incyte has a consensus price target of $114.96.
The stock price for Incyte (NASDAQ: INCY) is $116.5 last updated October 1, 2026 at 6:45 PM EDT.
There are no upcoming dividends for Incyte.
Incyte does not have any upcoming earnings scheduled.
There is no upcoming split for Incyte.
Incyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
